News

Video

Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF

Author(s):

Jamile Shammo, MD,Naveen Pemmaraju, MD

Abdulraheem Yacoub, MD, details the side effect profiles of the approved JAK inhibitors for myelofibrosis treatment.

Related Videos
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Justin M. Watts, MD
Michael R. Grunwald, MD, FACP
Related Content
stock.adobe.com
December 16th 2024

OB756 Showcases Favorable Tolerability in JAK Inhibitor–Naive Myelofibrosis

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Imetelstat in Lower-Risk MDS | Image credit: LASZLO – stock.adobe.com
December 13th 2024

CHMP Offers Positive Opinion for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

Courtney D. DiNardo, MD, MSCE
November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Navtemadlin in Relapsed/Refractory Myelofibrosis | Image Credit: © Свет Лана – stock.adobe.com
December 9th 2024

Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis

Myelodysplastic Syndrome | Image Credit: © LASZLO – stock.adobe.com
December 7th 2024

Smoking May Increase Genetic Mutations, Disease Progression in MDS